Bristol Tequin Labeling Update Includes New Indication, Glucose Warning
Executive Summary
A supplemental approval for Bristol-Myers Squibb's Tequin adds an indication for uncomplicated skin and skin structure infections - but also adds language on QT prolongation and blood glucose disturbances